Palisade Bio shareholders approve reverse stock split (1:10-1:50) and warrant issuance of up to 110.4M shares

PALISADE BIO, INC.

Reverse split ratio range 1-for-10 to 1-for-50 approved at Oct 4 special meeting; 45.2M votes for, 2.9M against.
Issuance of up to 110.4M shares upon exercise of Series 1 and 2 warrants approved at Oct 6 meeting; 5.5M for, 4.0M against.
Authorized share reduction from 300M to 280M approved at Oct 6 meeting; 11.5M votes for, 1.2M against.
Reverse split must be effected before 2023 annual meeting; exact ratio set by Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.